Condition: Advanced Malignant Solid Tumors · Sponsor: Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
This study is a multicenter, open phase I clinical study of dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in patients with advanced malignant solid tumors.
This description comes directly from the study's public registry record.
Ning Li, M.D. · 8610-87788713 · lining@cicams.ac.cn
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06717750